The recall of drugs against hypertension increases again

The drug is recalled because the active ingredient has been tested positive for N-Nitrosodiethylamine or NDEA, a suspected carcinogen for both humans and animals, used in gasoline as stabilizer for industrial products and as a lubricant additive, according to the National Institutes of Health.

The ingredient was manufactured by Zhejiang Huahai Pharmaceutical Company Co. Ltd. The FDA has put the Chinese company on alert at the end of September, which means that all of its active pharmaceutical products and finished products will not be allowed to enter the United States. The FDA made this decision after an inspection of the facility.

Several pills containing valsartan, another drug used by cardiac patients, have been recalled since July. The drugs were contaminated with NDEA or NDMA, N-nitrosodimethylamine, an impurity that is also considered a possible carcinogen by the US Environmental Protection Agency.

NDMA is an organic chemical used in the manufacture of liquid rocket fuel. It comes from the manufacture of certain pesticides and the processing of fish. It can be introduced unintentionally into the manufacture through certain chemical reactions.

The FDA is testing all the heart medications called ARAs to detect these impurities.

According to the FDA, the latest recall concerns less than 1% of the total pharmaceutical products containing losartan in the US market.

If your medicine is on the recall list, the FDA suggests taking it until your doctor or pharmacist replaces it. As all drugs based on valsartan and irbesartan are not affected by the recall, you may be able to upgrade to a version offered by another company.

He estimated that if 8,000 people took the highest dose of valsartan (320 milligrams) containing NDMA in these recalled batches for four years, there could be a new cancer case in the lifetime of 8,000 people . Many patients take a much lower dose of valsartan and, as a result, their risks are theoretically much lower.

The FDA has announced that it will continue testing all products containing valsartan and similar drugs for the presence of impurities.